Clinical Trial Update: A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating JNJ-64304500 as add-on therapy for active Crohn's disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• JNJ-64304500

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Crohn Disease | Phase 2 | Status: WITHDRAWN